Conference Coverage
April 16, 2021
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Conference Coverage
April 08, 2021
Significant disparities in technological knowledge and access to telehealth exist among cancer patients and are largely associated with demographic characteristics.

Conference Coverage
April 07, 2021
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Conference Coverage
April 06, 2021
Patients with NSCLC who receive pembrolizumab with chemotherapy are more likely to remain on therapy past 90 days than those who received chemotherapy alone.